Clinical trials
Chronic Leukemia clinical trials
Below are recruiting chronic leukemia clinical trials, each written for real people, not researchers. We’re tracking 306 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06043674RecruitingPhase 2
Glofitamab alone or with other drugs for Richter's transformation
This trial tests a drug called glofitamab, alone or combined with other drugs, for people whose chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) has changed into a faster-growing lymphoma (Richter's transformation). The goal is to see how well these treatments work and which combination might be best.
Atlanta, GeorgiaAges 18 years+ - NCT06130787Recruiting
Using your body's age to personalize CML treatment
This study looks at how your 'biological age' (how old your body seems) affects how well you do on targeted therapy for chronic myeloid leukemia. It aims to personalize your care by combining age and frailty information.
AnnecyAges 18 years+ - NCT06151730Recruiting
Managing blood pressure and heart risks during BTKi treatment
This study looks at how well blood pressure is managed and whether heart problems can be prevented in people with certain blood cancers who are taking a type of targeted therapy called a BTKi. It aims to help you stay healthier during treatment.
Rochester, MinnesotaAges Any age - NCT06159491RecruitingPhase 1/Phase 2
Pacritinib for chronic myelomonocytic leukemia (CMML)
This trial tests a drug called pacritinib for people with CMML. It's for those who haven't had JAK inhibitor therapy before and may have had only one cycle of other treatments.
New York, New YorkAges 18 years+ - NCT06218628RecruitingPhase 1
Pacritinib and talazoparib for bone marrow cancers unresponsive to prior therapy
This trial tests a combination of two drugs (pacritinib and talazoparib) for people with certain bone marrow cancers that have not responded well to standard JAK2 inhibitor therapy. The goal is to see if this combination can help shrink the spleen, improve symptoms, or slow disease progression.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06390306Recruiting
Combination therapy for advanced CML
This trial tests a new combination of three drugs (a third-generation TKI, azacitidine, and a Bcl-2 inhibitor) for people with chronic myeloid leukemia that has progressed to a more advanced phase (myeloid blast phase). The goal is to see if this combination is safe and effective.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06466122RecruitingPhase 2
Pirtobrutinib plus Venetoclax for resistant CLL or SLL
This trial tests two oral targeted drugs—pirtobrutinib and venetoclax—for people with CLL or SLL whose disease has continued to grow despite taking a BTK inhibitor (such as ibrutinib, acalabrutinib, or zanubrutinib). The goal is to see if this combination can control the cancer when a BTK inhibitor alone is no longer working.
Columbus, OhioAges 18 years+ - NCT06514534RecruitingPhase 2
Asciminib for CML with T315I mutation and ponatinib problems
This trial tests a new drug called asciminib for people with CML who have a specific genetic change (T315I) and cannot take or did not benefit from the drug ponatinib. The goal is to see if asciminib can help control the leukemia.
BordeauxAges 18–99 - NCT06528301RecruitingPhase 1
Trial of UB-VV111 with or without rapamycin for B-cell cancers
This trial tests a new therapy called UB-VV111, alone or with rapamycin, in people with certain types of lymphoma or leukemia that have come back or not responded to treatment. The goal is to see if it's safe and effective.
Duarte, CaliforniaAges 18 years+ - NCT06536452Recruiting
How blood cell production differs in CLL, MBL, and healthy people
This trial studies how the body makes blood cells in people with chronic lymphocytic leukemia (CLL), a related condition called monoclonal B-cell lymphocytosis (MBL), and in healthy volunteers matched by age. The goal is to understand differences that may help improve treatment or monitoring.
Rochester, MinnesotaAges 40 years+ - NCT06548152Recruiting
Quality of life for CLL patients on acalabrutinib
This study looks at quality of life in people with CLL who are taking acalabrutinib for the first time. It uses data already collected from a real-world database to see how patients feel and function.
Saint-AffriqueAges Any age - NCT06636175RecruitingEarly Phase 1
New imaging test for blood cancers
This study tests a new imaging agent called 64Cu-LLP2A to see if it can better detect certain blood cancers like multiple myeloma and low-grade lymphomas. It aims to find tumors more clearly than standard scans, which could help your doctor plan the best care for you.
St Louis, MissouriAges 18 years+ - NCT06697184RecruitingPhase 1/Phase 2
Testing a slower start of sonrotoclax for blood cancers
This trial tests a new way to slowly increase the dose of the drug sonrotoclax when starting treatment for blood cancers like chronic lymphocytic leukemia (CLL) or mantle cell lymphoma (MCL). The goal is to see if this slower start is safer and better tolerated.
Tampa, FloridaAges 18 years+ - NCT03501576Recruiting
Testing a flu or COVID vaccine response in people with lymphoma
This study checks how your immune system responds after getting a vaccine. It focuses on people with different types of lymphoma, aiming to learn which immune responses can be measured and whether the vaccines are safe for you.
Atlanta, GeorgiaAges 18 years+ - NCT02889003RecruitingPhase 2
Second attempt to stop treatment after pioglitazone in CML
This trial tests if a short course of pioglitazone (a diabetes drug) before stopping your TKI therapy can help you stay in remission longer. It is for people with chronic myeloid leukemia (CML) who have already lost their remission after a first or later attempt to stop TKI treatment.
Le ChesnayAges 18 years+ - NCT06724536Recruiting
Study of gut bacteria and TKIs in chronic myeloid leukemia
This trial looks at how gut bacteria affect the way chronic myeloid leukemia (CML) patients respond to tyrosine kinase inhibitor (TKI) medications. It may help doctors understand why some people have better outcomes than others.
TorinoAges 18 years+ - NCT06784167Recruiting
Vaccine response after CAR-T for myeloma and lymphoma
This study looks at how well vaccines work in people with multiple myeloma or certain lymphomas after they receive CAR-T cell therapy. It aims to help doctors understand the best way to revaccinate patients to protect against preventable diseases.
Portland, OregonAges 18 years+ - NCT06860880Recruiting
Personalized program to fight cancer-related fatigue
This trial tests a personalized supportive care program that combines exercise, nutrition, and coaching to help reduce fatigue in people with certain slow-growing lymphomas. It aims to improve energy and quality of life.
Chapel Hill, North CarolinaAges 18 years+ - NCT06876649RecruitingPhase 4
Long-term safety study of Pirtobrutinib
This trial is for people who are already in a Lilly study taking pirtobrutinib. It looks at the long-term safety of the drug by continuing to monitor you.
Jacksonville, FloridaAges 18 years+ - NCT06916767RecruitingPhase 1
Study of BAFF CAR-T cells for CLL or SLL
This trial tests a new type of immune cell therapy (BAFF CAR-T cells) for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or not responded after at least two prior treatments, including a BTK inhibitor and a BCL2 inhibitor. The goal is to see if these engineered cells can fight the cancer.
Cleveland, OhioAges 18 years+ - NCT06958705RecruitingPhase 2
Testing venetoclax after BTK inhibitor for CLL
This trial tests giving venetoclax to people with CLL who are already taking a BTK inhibitor and have stable disease. The goal is to see if adding venetoclax can help eliminate any remaining CLL cells.
Nanjing, JiangsuAges 18–80 - NCT06971848Recruiting
Skin testing for biologic drug allergies
This trial checks if people can safely receive certain biologic drugs without allergic reactions, using skin tests to see how the body reacts. It may help find out if you are allergic to a biologic medicine you have taken before.
AngersAges 18 years+ - NCT07014917RecruitingPhase 2
Comparing two ways to take venetoclax and acalabrutinib for CLL/SLL
This trial tests whether taking venetoclax on an intermittent schedule (not every day) works as well as taking it continuously when combined with acalabrutinib for people with untreated CLL or SLL. It aims to find a treatment approach that might be just as effective but with fewer side effects.
Cincinnati, OhioAges 18 years+ - NCT07030400Recruiting
Quality of life study for adults with CLL or SLL
This study looks at how health-related quality of life changes in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) when starting a new treatment. The goal is to better understand what affects well-being during therapy.
Tampa, FloridaAges 18 years+
Hear when a new Chronic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for chronic leukemia?
- Yes. Clin2 currently lists 306 recruiting chronic leukemia studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a chronic leukemia trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a chronic leukemia trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.